ACAD · ACADIA Pharmaceuticals Inc.
$19.73
-2.86% last session
End-of-day data · close of 2026-10-23
Market cap
$3B
Enterprise value
$3B
Trailing P/E
8.9
Forward P/E
21.4
Dividend yield
0.0%
Beta
0.89
Avg volume
2M
Employees
1K
Daily Change %
-2.86%
5 Days Change
6.22%
10 Days Change
9.08%
30 Days Change
-20.13%
60 Days Change
-31.50%
Month to Day Change
2.11%
Year to Day Change
-23.96%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ACAD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
UBS
Neutral$23.00
+16.6% vs priceRBC Capital
Outperform$36.00
+82.5% vs priceDeutsche Bank
Buy$31.00
+57.1% vs priceCitigroup
Buy$33.00
+67.3% vs priceMorgan Stanley
Equal-Weight$28.00
+41.9% vs priceBank of America
Buy$30.00
+52.1% vs priceJP Morgan
Overweight$34.00
+72.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Needham | Reiterates | Buy | $35.00 |
| 2026-10-13 | UBS | Downgrade | Buy → Neutral | $49.00 → $23.00 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $37.00 → $36.00 |
| 2026-09-25 | Deutsche Bank | Maintains | Buy | $38.00 → $31.00 |
| 2026-09-25 | HC Wainwright & Co. | Maintains | Buy | $37.00 → $33.00 |
| 2026-09-25 | Citizens | Maintains | Market Outperform | $36.00 → $33.00 |
| 2026-09-25 | BMO Capital | Maintains | Outperform | $36.00 → $34.00 |
| 2026-09-25 | Needham | Maintains | Buy | $41.00 → $35.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 19.9% below the 50-day MA ($24.64).
- bearish: Price vs 200-day MA: Trading 17.2% below the 200-day MA ($23.84).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.35) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($18.62).
ACAD Price Chart
Loading chart for ACAD…
Fundamentals
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.